Clinical Case Challenges: Strategies to Optimize Primary Immunodeficiency Management
September 25, 2019
September 25, 2020
Scroll to the Bottom of this Information to Begin this Course
Sponsored by The Academy for Continued Healthcare Learning (ACHL).
Supported by an educational grant from Grifols.
- Physicians — maximum of 0.5 AMA PRA Category 1 Credit(s)™
All other healthcare professionals completing this course will be issued a statement of participation.
This activity is intended for immunologists, allergists, primary care providers, and other clinicians involved in the diagnosis and management of patients with primary immunodeficiencies.
Primary care providers, internists, and other general practitioners may be the first to see a patient with PI and require a level of awareness. Yet, a survey issued by the American Academy of Allergy Asthma and Immunology and Immune Deficiency Foundation found that only 4% of primary care practitioners were aware that guidelines existed for the diagnosis and management of primary immunodeficiency. Because symptoms can overlap with many other conditions and/or diseases, it is also important that either an allergist or an immunologist evaluate the patient to screen for PI. The management of PI patients on IgG therapy is extremely complex, and there are various immunoglobulin formulations/delivery systems with different risk/benefit profiles that must be individualized for diverse PI patients. Thus, this activity endeavors to increase the knowledge and competence of PCPs, internists, and other practitioners regarding the diagnosis and treatment of PI in an effort to enhance patient outcomes.
Upon completion of this activity, participants should be able to:
- Describe clinical strategies for optimizing interdisciplinary care models in PI therapy management.
- Evaluate clinical protocols for screening patients for PI, identifying PI causes, and targeting IgG therapy across patient populations.
- Compare and contrast novel immunoglobulin formulations/delivery systems, their risk/benefit profiles, and which patient populations novel formulations may benefit.
- Examine emerging research data on PI genotypes and phenotypes/other emerging diagnostic strategies, and how the data intersects with novel therapies, existing therapies, and targeted treatment strategies.
- Discuss optimal clinical communication strategies and related shared decision-making tactics for providing optimal management of PI patients.
Hey Jin Chong, MD, PhD
Division Director of Pediatric Allergy & Immunology
Associate Professor of Pediatrics
Children's Hospital of Pittsburgh
University of Pittsburgh Medical Center
Physician Continuing Medical Education
The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosures of Conflicts of Interest
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in a CME activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been resolved prior to this CME activity. The following financial relationships have been provided:
Hey Jin Chong, MD, PhD
- Advisory Board: Horizon Pharma
ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
Instructions for Participation and Credit
This activity will take approximately 30 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity and complete the posttest and evaluation. To receive credit, 80% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.
For questions about this activity, please contact Katlyn Cooper at firstname.lastname@example.org.
Course Viewing Requirements
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above.
Disclosure of Unlabeled Use
This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: None
The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.
This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.